title: Successful retreatment of allograft rejection with OKT3.
abstract: OKT3 is a murine monoclonal antibody to the CD3 antigen of human T lymphocytes. The production of human antimurine antibodies after treatment with OKT3 has been perceived as a major limitation to its extended use and reuse. Treatment of 142 patients with 168 courses of OKT3 resulted in the development of antimouse antibody in 28% of the patients. Twenty-six patients (16 kidney, 6 liver, 3 heart, 1 pancreas) have been retreated with 27 courses of OKT3. Eighteen patients had no antimurine antibodies present, and the rejection reversal rate was 83% (15/18). Six patients had a low-titer antimurine antibody present, and rejection reversal occurred in 5 (83%). Rejection was not reversed in 2 patients with a high-titer antibody. Development of antimurine antibody was more frequent in renal transplant recipients (33%) than in hepatic (12%) or cardiac transplant recipients (18%). We believe that this reflects the fact that concomitant immunosuppressive therapy is more likely to be reduced during OKT3 therapy in renal transplant recipients than in hepatic or cardiac transplant recipients. Retreatment of patients with no anti-OKT3 antibody resulted in depletion of CD3+ cells from the peripheral blood, but it took longer than in patients being treated with OKT3 for the first time. Similarly, serum OKT3 levels rose more slowly in retreated patients compared to first treatment. In retreating patients with a low-titer antimurine antibody, it often was necessary to increase the dose of OKT3 in order to achieve adequate serum OKT3 levels and to deplete CD3+ cells. De novo antimurine antibody developed in 4 of the 18 (22%) antibody-negative patients who were retreated. In conclusion, retreatment with OKT3 should not be considered unless the antibody status of the patient is known. Development of low-titer antibodies does not preclude successful retreatment with OKT3; however, alternate antirejection therapy should be used in patients with high-titer antimurine responses.
authors.affiliation: Department of Internal Medicine, University of Cincinnati Medical Center, OH 45267-0585.
authors.forename: M R
authors.initials: MR
authors.lastname: First
authors.forename: T J
authors.initials: TJ
authors.lastname: Schroeder
authors.forename: P E
authors.initials: PE
authors.lastname: Hurtubise
authors.forename: M E
authors.initials: ME
authors.lastname: Mansour
authors.forename: I
authors.initials: I
authors.lastname: Penn
authors.forename: R
authors.initials: R
authors.lastname: Munda
authors.forename: W F
authors.initials: WF
authors.lastname: Balistreri
authors.forename: J W
authors.initials: JW
authors.lastname: Alexander
authors.forename: D B
authors.initials: DB
authors.lastname: Melvin
authors.forename: J P
authors.initials: JP
authors.lastname: Fidler
mesh_terms: D000888:Antibodies, Anti-Idiotypic / Q000096:biosynthesis*; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis / Q000276:immunology*; D017252:CD3 Complex; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D016030:Kidney Transplantation; D016031:Liver Transplantation; D008214:Lymphocytes / Q000145:classification / Q000276:immunology; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D013997:Time Factors
chemical_list: D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell